ZNTL - Zentalis Pharmaceuticals

-

$undefined

N/A

(N/A)

Zentalis Pharmaceuticals NasdaqGM:ZNTL Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.

Location: 1359 Broadway, Suite 1710, New York, NY, 10018, United States | Website: https://zentalis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-200.4M

Cash

332.5M

Avg Qtr Burn

-37.88M

Short % of Float

12.36%

Insider Ownership

13.39%

Institutional Own.

80.35%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details
Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer

Phase 2

Data readout

Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details
Cyclin E1+ platinum-resistant ovarian cancer (PROC)

Phase 2

Data readout

Phase 2

Data readout

Phase 1b

Data readout

Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details
Ovarian cancer, Cancer, Platinum-resistant ovarian cancer

Phase 1b

Update

Phase 1

Update

Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details
Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer

Phase 1

Update

Failed

Discontinued

Failed

Discontinued

ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details
Cancer, relapsed or refractory light chain amyloidosis

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued